For research use only. Not for use in humans.

Zilovertamab vedotin

Synonyms: VLS-101;MK-2140

Zilovertamab vedotin (VLS-101, MK-2140) is an antibody-drug conjugate (ADC) composed of a humanised monoclonal antibody targeting ROR1 and the anti-mitotic cytotoxic agent monomethyl auristatin E (MMAE). It has potential for the treatment of lymphoid malignancies.

Zilovertamab vedotin

CAS No. 2376463-48-6

Click to purchase products related to Zilovertamab vedotin

Quality Control

Batch: D401301 Purity: 99% Protein concentration: 5.27mg/ml Endotoxin Level: <1EU/mg
99

Specificity

Name Citation RORγ
S18-000003 0
TMP778 0
Expand to Check More
1. "+" indicates inhibitory effect. Increased inhibition is marked by a higher "+" designation. 2. "✔" indicates inhibitory effect, but without specific value.

Mechanism of Action

Description
Zilovertamab vedotin (VLS-101, MK-2140) is an antibody-drug conjugate (ADC) composed of a humanised monoclonal antibody targeting ROR1 and the anti-mitotic cytotoxic agent monomethyl auristatin E (MMAE). It has potential for the treatment of lymphoid malignancies.
References

Product Details

CAS No. 2376463-48-6
ADC antiody Zilovertamab
ADC cytotoxin MMAE
Formulation 1xPBS
Storage
(From the date of receipt)
Store the undiluted solution at -20°C in the dark to avoid freeze-thaw cycles.

Comparison of Clones for

*Literature analysis of various clone (for this target) products available on the market shows that Selleck's selected clones are more frequently applied. (data until September 2024)

Clinical Trial Information

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT06717347 RECRUITING Drug: Cyclophosphamide|Drug: Doxorubicin|Drug: Prednisone|Dr Diffuse Large B-Cell Lymphoma Merck Sharp & Dohme LLC 2025-01-27 PHASE3
NCT05458297 ACTIVE_NOT_RECRUITING Drug: Nemtabrutinib Chronic Lymphocytic Leukemia; Mantle Cell Lymphoma; Follicular Lymphoma; Richter Transformation Lymphoma Merck Sharp & Dohme LLC 2022-07-21 PHASE2
NCT05406401 ACTIVE_NOT_RECRUITING Drug: Cyclophosphamide|Drug: Doxorubicin|Drug: Prednisone|Dr Lymphoma, Large B-Cell, Diffuse (DLBCL) Merck Sharp & Dohme LLC 2022-07-14 PHASE2
NCT06395103 RECRUITING B-cell Acute Lymphoblastic Leukemia; Diffuse Large B-cell Lymphoma; Burkitt Lymphoma; Neuroblastoma; Ewing Sarcoma Merck Sharp & Dohme LLC 2024-08-16 PHASE1; PHASE2
NCT05562830 RECRUITING Urothelial Carcinoma Merck Sharp & Dohme LLC 2022-11-16 PHASE1; PHASE2
NCT06890884 RECRUITING Drug: Cyclophosphamide|Drug: Doxorubicin|Drug: Prednisone|Dr Lymphoma, Large B-Cell, Diffuse Merck Sharp & Dohme LLC 2025-04-11 PHASE2

(data from https://clinicaltrials.gov, updated on 2026-09-03)

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.